Last $56.21 USD
Change Today -0.44 / -0.78%
Volume 200.7K
As of 4:15 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

steris corp (STE) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - $57.72
52 Week Low
02/5/14 - $39.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STERIS CORP (STE)

steris corp (STE) Related Bloomberg News

View More Bloomberg News

steris corp (STE) Related Businessweek News

No Related Businessweek News Found

steris corp (STE) Details

STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company’s Healthcare segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers; liquid chemical sterilant processing systems; washer/disinfector systems; general and specialty surgical tables; surgical and examination lights; equipment management systems; operating room storage cabinets; warming cabinets; scrub sinks; gastrointestinal endoscopy accessories; connectivity solutions, such as operating room integration, workflow, patient tracking, and instrument management; cleaning chemistries and sterility assurance products; and cleansing products, including hard surface disinfectants, and skin care and hand hygiene solutions. This segment also provides maintenance programs and repair services; sterilization and surgical management consulting services; information management and decision support services; and other support services comprising construction and facility planning, engineering support, device testing, customer education, hand hygiene process excellence, asset management/planning, and the sale of replacement parts. Its Life Sciences segment offers formulated cleaning chemistries, vaporized hydrogen peroxide generators; sterilizers; and high-purity water equipment, as well as various preventive maintenance programs and repair services. The company’s STERIS Isomedix Services segment provides contract processing services using gamma irradiation and ethylene oxide technologies; and microbial reduction services. It sells its products to end users, dealers, and distributors. The company was formerly known as Innovative Medical Technologies and changed its name to STERIS Corporation in 1987. STERIS Corporation was founded in 1985 and is headquartered in Mentor, Ohio.

6,000 Employees
Last Reported Date: 05/29/14
Founded in 1985

steris corp (STE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $788.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $351.8K
Senior Vice President and Group President of ...
Total Annual Compensation: $401.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $321.3K
Senior Vice President of Infection Prevention...
Total Annual Compensation: $312.6K
Compensation as of Fiscal Year 2014.

steris corp (STE) Key Developments

Steris Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Affirms Earnings Guidance for the Fiscal Year 2015

Steris Corporation reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported revenues of $412,643,000 against $367,652,000 a year ago. Income from operations was $44,168,000 against $41,012,000 a year ago. Net income was $24,537,000 against $32,317,000 a year ago. Earnings per share diluted were $0.41 against $0.54 a year ago. Net cash provided by operating activities was $46,353,000 against $32,697,000 a year ago. Capital spending was $23.3 million against $21.7 million a year ago. Adjusted net income per diluted share was $0.54 against $0.44 a year ago. Adjusted operating income was $55,971,000 against $46,062,000 a year ago. Adjusted net income was $32,049,000 against $26,153,000 a year ago. Net debt as on June 30, 2014 was $500,804,000 against as on $347,862,000 as on June 30, 2013. Based upon current trends, the company is affirmed its original outlook for fiscal 2015, which includes revenue growth in the range of 15% to 17% and adjusted earnings per diluted share in the range of $2.78 to $2.91 for the full fiscal year. The company anticipated a full year effective tax rate of approximately 35%. The company has worked to do to get to full year anticipated 15% margin rate.

Steris Corp. Increases Quarterly Dividend Payable September 23, 2014

The Board of Directors of Steris Corp. has authorized a two cent increase in its quarterly dividend to $0.23 per common share, representing the ninth consecutive year of dividend increases. The dividend is payable September 23, 2014 to shareholders of record at the close of business on August 26, 2014.

Steris Corp. to Report Q1, 2015 Results on Aug 05, 2014

Steris Corp. announced that they will report Q1, 2015 results Pre-Market on Aug 05, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STE:US $56.21 USD -0.44

STE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Catalent Inc $24.31 USD +0.09
Chemed Corp $103.78 USD -0.31
Teleflex Inc $108.99 USD -0.51
West Pharmaceutical Services Inc $44.01 USD +0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation STE Industry Range
Price/Earnings 27.8x
Price/Sales 2.0x
Price/Book 3.2x
Price/Cash Flow 27.6x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STERIS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at